mAIbe
mAIbe is an innovative biotechnology startup focused on the research, development, and production of anti-infective medicinal products. They leverage advanced, physics-informed artificial intelligence, specifically generative AI and synthetic biology, to create a data-driven platform for precise monoclonal antibody (mAb) design. This approach aims to reduce manufacturing costs, improve accessibility, and broaden the application of mAbs in combating infectious diseases, including those with pandemic potential. The company highlights that AI can significantly reduce drug discovery and development time and cost, potentially by up to 50% and 60% respectively, while increasing success rates. Their focus is on infectious diseases like HIV and RSV, as well as pandemic-potential viruses.
mAIbe
mAIbe is an innovative biotechnology startup focused on the research, development, and production of anti-infective medicinal products. They leverage advanced, physics-informed artificial intelligence, specifically generative AI and synthetic biology, to create a data-driven platform for precise monoclonal antibody (mAb) design. This approach aims to reduce manufacturing costs, improve accessibility, and broaden the application of mAbs in combating infectious diseases, including those with pandemic potential. The company highlights that AI can significantly reduce drug discovery and development time and cost, potentially by up to 50% and 60% respectively, while increasing success rates. Their focus is on infectious diseases like HIV and RSV, as well as pandemic-potential viruses.